Lion TCR Receives FDA Fast Track Designation for its HBV-specific TCR T Cell Therapy for Hepatocellular Carcinoma

SINGAPORE and GUANGZHOU, China and LOS ANGELES: SINGAPORE and GUANGZHOU, China and LOS ANGELES, Dec. 23, 2021 /PRNewswire/ -- Lion TCR Pte Ltd today announced that it has received Fast Track Designation from United States Food and Drug Administration (U.S. FDA) for LioCyx-M004, autologous T-cells transfected with mRNA encoding Hepatitis...

Click to view original post